{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:18:14Z","timestamp":1790050694645,"version":"4.0.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.clml.2016.08.003","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T14:42:58Z","timestamp":1470926578000},"page":"537-542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["The T Cell in Myeloma"],"prefix":"10.1016","volume":"16","author":[{"given":"Douglas","family":"Joshua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8541-9801","authenticated-orcid":false,"given":"Hayley","family":"Suen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Joy","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.08.003_bib1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma","volume":"138","author":"Pratt","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.08.003_bib2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.08.003_bib3","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002\u2013Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.08.003_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clml.2011.11.001","article-title":"How to manage neutropenia in multiple myeloma","volume":"12","author":"Palumbo","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2016.08.003_bib5","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1182\/blood-2015-03-631853","article-title":"CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRbeta repertoire","volume":"125","author":"Suessmuth","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.003_bib6","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.08.003_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-0609.1982.tb00563.x","article-title":"T\u00a0cells in monoclonal gammopathies","volume":"29","author":"Mellstedt","year":"1982","journal-title":"Scand J Haematol"},{"key":"10.1016\/j.clml.2016.08.003_bib8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2141.1983.tb02021.x","article-title":"Abnormal monoclonal antibody-defined helper\/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage","volume":"53","author":"Mills","year":"1983","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.08.003_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood.V98.1.23","article-title":"Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients","volume":"98","author":"Kay","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.003_bib10","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood-2008-03-143222","article-title":"Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma","volume":"112","author":"Dhodapkar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.003_bib11","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1182\/blood-2009-10-246660","article-title":"Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma","volume":"115","author":"Prabhala","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.003_bib12","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3109\/10428194.2013.825905","article-title":"Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state","volume":"55","author":"Favaloro","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2016.08.003_bib13","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1084\/jem.20031030","article-title":"Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy","volume":"198","author":"Dhodapkar","year":"2003","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clml.2016.08.003_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/cei.12196","article-title":"Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy","volume":"175","author":"Chan","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.clml.2016.08.003_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2012.067272","article-title":"Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry","volume":"98","author":"Pessoa de Magalhaes","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.08.003_bib16","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1084\/jem.20021650","article-title":"A\u00a0reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma","volume":"197","author":"Dhodapkar","year":"2003","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clml.2016.08.003_bib17","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1084\/jem.20042592","article-title":"Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients","volume":"201","author":"Chang","year":"2005","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clml.2016.08.003_bib18","doi-asserted-by":"crossref","first-page":"e65075","DOI":"10.1371\/journal.pone.0065075","article-title":"Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model","volume":"8","author":"Nur","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2016.08.003_bib19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1182\/blood-2012-06-435503","article-title":"Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma","volume":"121","author":"Richter","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.003_bib20","doi-asserted-by":"crossref","first-page":"23128","DOI":"10.18632\/oncotarget.7440","article-title":"Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?","volume":"7","author":"Favreau","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2016.08.003_bib21","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/leu.2015.104","article-title":"The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study","volume":"29","author":"Suen","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.08.003_bib22","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.3109\/10428190903216804","article-title":"Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma","volume":"50","author":"Brown","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2016.08.003_bib23","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1038\/bcj.2013.34","article-title":"Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg\/Th17 balance","volume":"3","author":"Bryant","year":"2013","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2016.08.003_bib24","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2012-03-416792","article-title":"CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis","volume":"120","author":"Brown","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.003_bib25","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1182\/blood.V98.10.2992","article-title":"Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10","volume":"98","author":"Brown","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.003_bib26","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/14653240410005357","article-title":"DC in multiple myeloma immunotherapy","volume":"6","author":"Turtle","year":"2004","journal-title":"Cytotherapy"},{"key":"10.1016\/j.clml.2016.08.003_bib27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.08.003_bib28","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.08.003_bib29","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/leu.2015.278","article-title":"Idiotype-specific CD4 T cells eradicate disseminated myeloma","volume":"30","author":"Haabeth","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.08.003_bib30","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1182\/blood-2002-04-1250","article-title":"T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma","volume":"101","author":"Hansson","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.003_bib31","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.3109\/10428190309178780","article-title":"Prediction of high affinity class I-restricted multiple myeloma idiotype peptide epitopes","volume":"44","author":"Szea","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2016.08.003_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.neo.2015.11.011","article-title":"Isolation of human CD138(+) microparticles from the plasma of patients with multiple myeloma","volume":"18","author":"Krishnan","year":"2016","journal-title":"Neoplasia"},{"key":"10.1016\/j.clml.2016.08.003_bib33","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.4049\/jimmunol.1202005","article-title":"Programmed death receptor-1\/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma","volume":"190","author":"Kearl","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2016.08.003_bib34","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1182\/blood-2005-04-1438","article-title":"Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma","volume":"106","author":"Jalili","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.003_bib35","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1158\/1078-0432.CCR-13-2234","article-title":"Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer\u2013response","volume":"19","author":"Sznol","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2016.08.003_bib36","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/leu.2011.120","article-title":"Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma","volume":"25","author":"Bae","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.08.003_bib37","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1182\/blood-2010-08-299396","article-title":"Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma","volume":"117","author":"Rapoport","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.003_bib38","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1182\/blood-2007-07-099366","article-title":"RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses","volume":"111","author":"Schmitt","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.003_bib39","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.4161\/21645515.2014.982993","article-title":"Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies","volume":"10","author":"Pyzer","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.clml.2016.08.003_bib40","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1182\/blood-2015-04-640532","article-title":"The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy","volume":"126","author":"Walz","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.003_bib41","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2016.84","article-title":"Multiple myeloma causes clonal T cell immunosenescence: Identification of potential novel targets for promoting tumor immunity and implications for checkpoint blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.08.003_bib42","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1182\/blood-2009-10-246991","article-title":"Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenstrom macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy","volume":"115","author":"Li","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.003_bib43","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.molmed.2007.01.005","article-title":"Immune remodeling: lessons from repertoire alterations during chronological aging and in immune-mediated disease","volume":"13","author":"Vallejo","year":"2007","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.clml.2016.08.003_bib44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2141.2000.02131.x","article-title":"T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells","volume":"110","author":"Raitakari","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.08.003_bib45","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/leu.2014.204","article-title":"Phospho-flow detection of constitutive and cytokine-induced pSTAT3\/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma","volume":"29","author":"Brown","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.08.003_bib46","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/bmt.2015.143","article-title":"Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma","volume":"50","author":"Rosko","year":"2015","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.clml.2016.08.003_bib47","doi-asserted-by":"crossref","first-page":"e59756","DOI":"10.1371\/journal.pone.0059756","article-title":"Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells","volume":"8","author":"Andre","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2016.08.003_bib48","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cellsig.2011.12.006","article-title":"Emerging role of NF-kappaB signaling in the induction of senescence-associated secretory phenotype (SASP)","volume":"24","author":"Salminen","year":"2012","journal-title":"Cell Signal"},{"key":"10.1016\/j.clml.2016.08.003_bib49","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.cell.2008.03.039","article-title":"Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network","volume":"133","author":"Kuilman","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.clml.2016.08.003_bib50","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12885-015-1078-3","article-title":"Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region","volume":"15","author":"Berenstein","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2016.08.003_bib51","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.08.003_bib52","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2015-03-632919","article-title":"Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy","volume":"126","author":"Dhodapkar","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.08.003_bib53","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.08.003_bib54","doi-asserted-by":"crossref","first-page":"e0139867","DOI":"10.1371\/journal.pone.0139867","article-title":"PDL1 Expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy","volume":"10","author":"Sponaas","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2016.08.003_bib55","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clml.2016.08.003_bib56","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/ni0903-815","article-title":"What is trogocytosis and what is its purpose?","volume":"4","author":"Joly","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clml.2016.08.003_bib57","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nri2020","article-title":"Intercellular transfer of cell-surface proteins is common and can affect many stages of an immune response","volume":"7","author":"Davis","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.clml.2016.08.003_bib58","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.4161\/onci.22032","article-title":"Trogocytosis generates acquired regulatory T cells adding further complexity to the dysfunctional immune response in multiple myeloma","volume":"1","author":"Brown","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clml.2016.08.003_bib59","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-015-0114-8","article-title":"Trogocytic intercellular membrane exchanges among hematological tumors","volume":"8","author":"LeMaoult","year":"2015","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2016.08.003_bib60","doi-asserted-by":"crossref","first-page":"e35981","DOI":"10.1371\/journal.pone.0035981","article-title":"Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent","volume":"7","author":"Feyler","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2016.08.003_bib61","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-1108","article-title":"Checkpoint inhibition of KIR2D with the monoclonal antibody IPH2101 induces contraction and hyporesponsiveness of NK-cells in patients with myeloma","author":"Carlsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2016.08.003_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02587.x","article-title":"Cancer immunoediting from immune surveillance to immune escape","volume":"121","author":"Kim","year":"2007","journal-title":"Immunology"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016303779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016303779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:37Z","timestamp":1761870457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016303779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":62,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S2152265016303779"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.08.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The T Cell in Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2016 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}